Tandem Therapeutics AG

Most drug development is focused on targeting cells, overlooking the extracellular matrix that surrounds the cells. Presence of excessive matrix proteins are linked to therapeutic resistance and poor patient outcomes in fibrotic tumors and organ fibrosis. The matrix offers druggable biological real-estate to targets nodes that drive disease progression. At Tandem Therapeutics our goal is to precision target this barrier and bring drugs to this disease extracellular matrix thereby enhancing safety and efficacy. Using evolutionarily optimised peptides, we are decoding complex matrix-disease biology to create breakthrough solutions for patients burdened with fibrotic diseases.